TransThera Biosciences Co. Ltd
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From TransThera Biosciences Co. Ltd
Investors continue to focus on anticancer therapies including small molecule drugs and cell therapies in China.
US-based, China-focused CANbridge moves into cholestatic liver disease and enzyme replacement therapy via two deals. Plus deals involving LegoChem, TransThera, Morepen, Daiichi Sankyo, Geneseeq, Innocare, Biosplice, Sirnaomics and Walvax.
Although there weren’t many large-scale partnerships as in previous years, Korean biopharma firms were involved in a broad range of deals across diverse therapeutic areas in 2020, with ADCs, oncology and domestic alliances emerging as key trends.
Although SRF813 isn’t likely to reach the clinic until 2021, GSK likes cell therapy’s monotherapy and combination potential. Lilly bids $880m to acquire neurodegenerative cell therapy firm Prevail.
- Other Names / Subsidiaries
- Nanjing Transtherabio Sciences Co. Ltd.
- Nanjing TransThera Biosciences Co. Ltd.